SCHEMBL16184134

SCHEMBL16184134

CNc1nc(-c2cccnc2)nc2c(OC)c(Cl)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 4/20 0.54
▸ CYP3A4 P08684 4/20 0.54
▸ CLK4 Q9HAZ1 3/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ ABCG2 Q9UNQ0 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ USP2 O75604 3/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ ABCB1 P08183 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ CYP19A1 P11511 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184159 0.85 NPC1 (0.44) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL14358731 0.83 CYP1A2 (0.56) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184135 0.82 CYP1A2 (0.50) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184140 0.81 CYP1A2 (0.51) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184141 0.81 CYP1A2 (0.48) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184138 0.80 CYP1A2 (0.47) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184142 0.80 CYP3A4 (0.47) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184139 0.79 CYP1A2 (0.47) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184137 0.79 CYP1A2 (0.47) CYP1A2CYP3A4CLK4CYP2D6CYP2C9
SCHEMBL16184136 0.78 CYP1A2 (0.46) CYP1A2CYP3A4CLK4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB CYP1A2 2971/4885CYP3A4 4456/4885CLK4 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback